Evidence map›Paper›PMID 40919143›Full record

ArticleFrontiers in oncology2025

Hypoxia promotes pancreatic adenocarcinoma progression by stabilizing ID1 via TRIM21 suppression.

Rui Cheng, Yuanjun Tang, Xuedi Cao, Zhanya Huang, Yunyun Guo, Renjing Jin, Yan Wang, Yang Liu, Lixiang Xue, Yuqing Wang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rui ChengPeking University Third Hospital Cancer Center, Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.
Yuanjun TangCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Xuedi CaoCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Zhanya HuangPeking University Third Hospital Cancer Center, Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.
Yunyun GuoPeking University Third Hospital Cancer Center, Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.
Renjing JinPeking University Third Hospital Cancer Center, Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.
Yan WangCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Yang LiuCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Lixiang XueCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Yuqing WangCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pancreatic adenocarcinoma (PAAD) is a highly aggressive malignancy characterized by a profoundly hypoxic tumor microenvironment, which fosters tumor progression and confers resistance to therapy The oncogenic regulator ID1has been implicated in PAAD malignancy, however, the mechanisms underlying hypoxia-induced stabilization of ID1 and the role of ubiquitin-mediated degradation remain poorly understood. Elucidating these pathways is essential for identifying novel therapeutic targets for PAAD. Methods: In this study, we examined ID1 expression in PAAD tissues and cell lines using publicly available databases and in vitro models. We simulated hypoxic conditions to assess their effects on ID1 expression and tumor cell behaviors, including proliferation, migration, and invasion. Protein stability was investigated via cycloheximide chase, proteasome and autophagy inhibition, and ubiquitination assays. Mass spectrometry identified TRIM21 as an E3 ubiquitin ligase interacting with ID1. To investigate its regulatory role, we generated stable TRIM21 knockdown and overexpression pancreatic cancer cell lines. Finally, in vivo xenograft experiments were conducted to evaluate the impact of ID1 and TRIM21 on tumor growth. Results: ID1 was markedly overexpressed in PAAD tissues and cell lines, correlating with advanced tumor stage, metastasis, and reduced patient survival. Hypoxia elevated ID1 protein levels without significantly affecting its mRNA, suggesting post-translational stabilization. Mechanistic studies revealed that hypoxia inhibits ubiquitin-proteasome-mediated degradation of ID1 by downregulating TRIM21, an E3 ubiquitin ligase responsible for ID1 ubiquitination. TRIM21 knockdown restored ID1 levels and promoted tumor cell function, whereas TRIM21 overexpression suppressed these malignant phenotypes and mitigated hypoxia-induced aggressiveness. In vivo, ID1 silencing impeded, while TRIM21 knockdown accelerated, pancreatic tumor growth, confirming their opposing roles in tumor progression. Discussion: Our findings demonstrate that hypoxia drives pancreatic tumor progression by downregulating TRIM21, leading to stabilization of the oncogenic protein ID1. The TRIM21-ID1 axis emerges as a promising therapeutic target for PAAD, suggesting that restoring TRIM21-mediated ID1 degradation could counteract hypoxia-induced malignancy.

Indexed as

hypoxiaId1pancreatic adenocarcinomaTRIM21ubiquitination

Identifiers

PMID40919143
PMCPMC12408324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.